Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639956 | PMC |
| http://dx.doi.org/10.1136/postgradmedj-2020-139107 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Lenalidomide-induced arthritis: A case report and review of literature and pharmacovigilance databases.
J Oncol Pharm Pract
March 2022
Department of Hematology, 54909Institut Universitaire du Cancer-Oncopole, France.
Introduction: Lenalidomide is an immunomodulatory agent with multiple mechanisms of action, and treatment with lenalidomide is associated with adverse events such as thrombosis and abdominal pain; nonetheless, other rarer adverse events do exist, with few knowledge from physicians and pharmacists. For such adverse events, pharmacovigilance databases are of great interest.
Case Report: A 71-year-old patient with no rheumatologic history, in complete remission of a mantle-cell lymphoma following rituximab, doxorubicin, vincristine, cyclophosphamide, and prednisone induction, received a maintenance treatment with rituximab and lenalidomide.
Synergistic Effect and Tolerance of Concurrent Radiotherapy and Lenalidomide Use in Relapsing Mantle Cell Lymphoma: A Case Report.
Perm J
November 2020
Radiotherapy Department, Abderrahman Mami Hospital, Ariana, Tunisia.
Introduction: Mantle cell lymphoma is an aggressive disease. Limited treatment options are available for refractory or relapsing presentation. We report the first case, to the best of our knowledge, of concurrent radiotherapy and lenalidomide use in this setting, focusing on its possible synergy and tolerance.
View Article and Find Full Text PDFLenalidomide-induced focal myocarditis mimicking acute ST segment elevation myocardial infarction.
Postgrad Med J
December 2021
Medicine, University of Hong Kong, Hong Kong, China
Lenalidomide-induced regenerative macronodules infarction in a cirrhosis patient.
Clin Res Hepatol Gastroenterol
April 2013
Service de radiologie, hôpital Saint-Antoine, groupe hospitalier Saint-Antoine, AP-HP, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France.
Hepatic regenerative macronodules observed in hepatic cirrhosis are sensitive to ischemia. Lenalidomide is a thalidomide analog used for the treatment of myelodysplastic syndromes, with pleiotropic activities including induction of apoptosis, inhibition of angiogenesis and broad immunomodulatory effects. It has been approved by the Food and Drug Administration (FDA) in the United States and by the European Medicines Agency (EMEA) in 2007 for the use in combination with dexamethasone in the treatment of relapsed or refractory multiple myeloma.
View Article and Find Full Text PDFBackground: A 24-year-old female patient was diagnosed with classic Hodgkin's lymphoma in clinical stage II, and combination chemotherapy followed by radiotherapy was initiated. During the following 5 years, the disease progressed despite several standard therapeutic approaches, including autologous and allogeneic stem cell transplantation.
Methods: Lenalidomide (25 mg daily) treatment was then initiated in a continuous dosing schedule.